Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

Nuclear Pharm-Assist device for patients seeking care for cardiac, cancer diseases

Positron Corporation is a molecular imaging solutions company focused on Nuclear Cardiology states that its proprietary product line also includes unique solutions for the oncology community designed to enhance its position in this industry.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.

30 Apr 2010

Study identifies extracapsular LNI as a negative prognostic factor for esophageal cancer

There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional esophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected esophageal cancer.

30 Apr 2010

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Calypso Medical Technologies, Inc., a developer of non-ionizing real-time localization technology used for the precise tracking of tumor targets, and Cancer Treatment Centers of America, a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment, announced today that with the installation of the Calypso System at the CTCA at Southwestern Regional Medical Center in Tulsa, Okla., Calypso's real-time tumor tracking technology is now available at all CTCA centers nationwide.

30 Apr 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

At the 2010 American Association of Neurological Surgeons Annual Meeting, May 1-5 at the Pennsylvania Convention Center, Elekta will host a series of presentations highlighting Elekta Neuromag, a tool that measures and records brain activity using magnetoencephalography technology.

From Elekta 30 Apr 2010

CT Dose Summit to establish freely available guidelines for performing CT scans

A national "CT Dose Summit" in Atlanta, GA this week will bring together some of the world's leading experts on medical imaging to lay the foundation for assembling optimized guidelines for performing CT scans -- a common medical imaging procedure that uses X-rays to show cross-sectional images of the body.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

Clarient reports 14.8% increase in first quarter 2010 revenue

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Adult glioblastoma continues to be a difficult disease to treat, so healthcare professionals must have the most up-to-date information regarding optimal methods for diagnostic imaging and treatment of these tumors. Awareness of novel agents in clinical trials is also critical to providing the best care.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

29 Apr 2010

Oncology News and Research

Further Reading

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Nuclear Pharm-Assist device for patients seeking care for cardiac, cancer diseases

REGN reports net loss of $30.5M for first-quarter 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Study identifies extracapsular LNI as a negative prognostic factor for esophageal cancer

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

CT Dose Summit to establish freely available guidelines for performing CT scans

TenX Biopharma signs Clinical Trial Agreement with NCI

PROVENGE receives FDA approval for treatment of CRPC

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Women with family history of breast cancer face increase risk of ovarian cancer

Clarient reports 14.8% increase in first quarter 2010 revenue

Canadian researchers identify new therapeutic target for lung cancer

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News